JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
JW Therapeutics is a cell therapy company driven by scientific and technological innovation. The company is committed to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improving their quality of life and bringing them a new hope. JW Therapeutics is a joint-venture company established by Juno Therapeutics, a global leading cell-based cancer immunotherapy company, and WuXi AppTec, a leading pharmaceutical, biotechnology, and medical device R&D platform company with global operations. By leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and China expertise, JW Therapeutics aims to revolutionize cancer treatment and to build a leading innovation-driven cell-therapy company.